2fjp: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2fjp" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fjp, resolution 2.40Å" /> '''Human dipeptidyl pe...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2fjp.gif|left|200px]]<br />
[[Image:2fjp.gif|left|200px]]<br /><applet load="2fjp" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2fjp" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2fjp, resolution 2.40&Aring;" />
caption="2fjp, resolution 2.40&Aring;" />
'''Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor'''<br />
'''Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor'''<br />


==Overview==
==Overview==
A series of beta-substituted biarylphenylalanine amides were synthesized, and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the, treatment of type 2 diabetes. Optimization of the metabolic profile of, early analogues led to the discovery of, (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, ,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally, active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral, bioavailability in preclinical species, and in vivo efficacy in animal, models. Compound 6 was selected for further characterization as a, potential new treatment for type 2 diabetes.
A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1 ,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes.


==About this Structure==
==About this Structure==
2FJP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with NAG and S14 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dipeptidyl-peptidase_IV Dipeptidyl-peptidase IV], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.14.5 3.4.14.5] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2FJP OCA].  
2FJP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=NAG:'>NAG</scene> and <scene name='pdbligand=S14:'>S14</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dipeptidyl-peptidase_IV Dipeptidyl-peptidase IV], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.14.5 3.4.14.5] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FJP OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Becker, J.W.]]
[[Category: Becker, J W.]]
[[Category: Patel, S.B.]]
[[Category: Patel, S B.]]
[[Category: Scapin, G.]]
[[Category: Scapin, G.]]
[[Category: NAG]]
[[Category: NAG]]
Line 24: Line 23:
[[Category: dimer]]
[[Category: dimer]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:06:28 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:22:05 2008''